ASTRO 2017: Updates in HPV-Positive Head and Neck Cancer

Video
Conference|American Society for Radiation Oncology Annual Meeting (ASTRO)

This video highlights studies on HPV-positive head and neck cancer presented at the 2017 ASTRO Annual Meeting.

In this video, David Raben, MD, of the University of Colorado Cancer Center, highlights selected studies on the treatment of HPV-positive head and neck cancer presented at the 2017 American Society for Radiation Oncology (ASTRO) Annual Meeting, held September 24–27 in San Diego.

Raben was the discussant for a head and neck cancer session that featured the following abstracts:

• Quantification of HPV-16 in circulating tumor DNA during de-intensified chemoradiotherapy for favorable-risk HPV-associated oropharyngeal squamous cell carcinoma (abstract 92)

• Induction chemotherapy followed by concurrent chemoradiation vs concurrent chemoradiation alone in the definitive management of p16-positive oropharyngeal cancer with low-neck or N3 disease (abstract 93)

• Nodal radiographic prognostic factors in the new stage I p16-positive oropharyngeal cancer of the AJCC 8th edition: is all N1 disease the same? (abstract 293)

• Long-term survival in oligometastatic head and neck cancer (abstract 296)

Recent Videos
Treatment with toripalimab does not yield the same vascular toxicity seen with pembrolizumab in patients with advanced or metastatic nasopharyngeal carcinoma, according to Barbara Burtness, MD.
Overall survival also appears to improve with toripalimab compared with chemotherapy among patients with metastatic or advanced nasopharyngeal carcinoma.
Those with breast cancer who have undergone implant-based reconstruction following mastectomy have similar outcomes with hypofractionated vs conventionally fractionated radiotherapy.
PSMA-targeting PET ligand 18F-rhPSMA-7.3 yielded high detection rates for patients with recurrent prostate cancer regardless of factors such as PSA levels, PSA doubling time, or Gleason scores, according to Benjamin H. Lowenritt, MD, FACS.
Pooling data with other radiation trials, looking more closely at central non-small cell lung cancer, and exploring secondary outcomes represent the next steps in terms of analyzing stereotactic body radiation (SBRT) vs conventional hypofractionated radiotherapy (CRT), according to Anand Swaminath, MD.
Findings from the phase 3 CALLA trial indicated that intensity modulated radiation therapy was administered in 88.1% of patients with high-risk locally advanced cervical cancer treated with durvalumab and chemoradiotherapy vs 88.1% with placebo and chemoradiotherapy.
Anand Swaminath, MD, reviews the design of the phase 3 LUSTRE trial comparing a 3-week conventional radiotherapy regimen with stereotactic body radiotherapy among patients with stage I medically inoperable non-small cell lung cancer.
Future focuses following the phase 3 SPOTLIGHT trial will include identifying sites of recurrence and different intensity levels for 18F-rhPSMA-7.3 in suspected recurrent prostate cancer, according to Benjamin H. Lowenritt, MD, FACS.
Stereotactic body radiation therapy yielded numerical improvements in terms of local control compared with conventional hypofractionated radiotherapy among patients with stage I medically inoperable non-small cell lung cancer, according to findings from the phase 3 LUSTRE trial.
Jyoti S. Mayadev, MD, indicated that durvalumab (Imfinzi) plus chemotherapy resulted in low rates of high-grade late-onset toxicities in the phase 3 CALLA trial, which may be due in part to the quality of the technology employed during the study.
Related Content
Phase 2 data may support petosemtamab as a best-in-class treatment for frontline HNSCC, according to Jérôme Fayette, MD.

Petosemtamab Combo Shows Responses, Tolerability in Head and Neck Cancer

Kristi Rosa
June 5th 2024
Article

Phase 2 data may support petosemtamab as a best-in-class treatment for frontline HNSCC, according to Jérôme Fayette, MD.

David Sher on the Updated ASTRO Guidelines for Oropharyngeal Cancer

David Sher on the Updated ASTRO Guidelines for Oropharyngeal Cancer

David J. Sher, MD, MPH
September 15th 2017
Podcast

In this interview we discuss new clinical guidelines from ASTRO on the use of radiotherapy in treating oropharyngeal cancer.

Head and neck cancer

Early Intervention, Regular Assessment Can Grasp Symptom Course for Head and Neck Cancer Therapy

Darlene Dobkowski, MA
April 28th 2024
Article

Nurses must increase the frequency of their assessments for early intervention of patients who undergo treatment for their head and neck cancer, in an effort to truly individualized care.

FDA Gives Fast Track Designation to LYT-200 in Advanced Head and Neck Cancers

FDA Gives Fast Track Designation to LYT-200 in Advanced Head and Neck Cancers

Ariana Pelosci
April 12th 2024
Article

LYT-200 is currently being investigated for those with solid tumors and hematologic malignancies.

Findings suggest that harnessing the tumoral node microenvironment may improve the ability to predict extracapsular nodal extensions in patients with oropharyngeal carcinoma.

AI-Based Model May Improve Prediction of ECE in Oropharyngeal Cancer

Russ Conroy
March 5th 2024
Article

Findings suggest that harnessing the tumoral node microenvironment may improve the ability to predict extracapsular nodal extensions in patients with oropharyngeal carcinoma.

Prognostic Factors Linked With Poor Locoregional Control in Tongue Cancer | Image Credit: © freshidea - stock.adobe.com.

Prognostic Factors Linked With Poor Locoregional Control in Tongue Cancer

Gina Mauro
March 5th 2024
Article

Patients with factors such as lymphovascular space invasion or positive glossectomy specimen margins may be considered for adjuvant radiotherapy to optimize disease control of tongue squamous cell carcinoma.